These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1937361)

  • 21. [Plasma fibronectin in chronic liver disease--marker of fibrosis?].
    Simon K; Zalewska M; Gładysz A; Rotter K; Piszko P; Głowacki A
    Przegl Lek; 1995; 52(4):129-32. PubMed ID: 7638358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of zinc and thymulin in plasma from patients with Crohn's disease.
    Mocchegiani E; Brignola C; Iannone P; Campieri M; Pasquali M; Lanfranchi GA; Barbara L; Fabris N; Licastro F
    J Clin Lab Immunol; 1990 Jun; 32(2):79-84. PubMed ID: 1967043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity.
    Sategna-Guidetti C; Pulitanò R; Fenoglio L; Bologna E; Manes M; Camussi G
    Recenti Prog Med; 1993 Feb; 84(2):93-9. PubMed ID: 8465094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total parenteral nutrition modifies the acute phase response to Crohn's disease.
    Carlson GL; Gray P; Barber D; Shaffer JL; Mughal M; Irving MH
    J R Coll Surg Edinb; 1994 Dec; 39(6):360-4. PubMed ID: 7532715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between clinical data and histology of the large bowel in Crohn's disease and ulcerative colitis.
    Schmitz-Moormann P; Himmelmann GW; Brandes JW
    Pathol Annu; 1985; 20 Pt 1():281-301. PubMed ID: 3991239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deficiency of interstitial cells of Cajal in the small intestine of patients with Crohn's disease.
    Porcher C; Baldo M; Henry M; Orsoni P; Julé Y; Ward SM
    Am J Gastroenterol; 2002 Jan; 97(1):118-25. PubMed ID: 11808934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma fibronectin in Crohn's disease.
    Allan A; Wyke J; Allan RN; Morel P; Robinson M; Scott DL; Alexander-Williams J
    Gut; 1989 May; 30(5):627-33. PubMed ID: 2731755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?
    He JS; Tan JY; Li XZ; Feng R; Xiong SS; Lin SN; Qiu Y; Mao R
    J Dig Dis; 2020 Jun; 21(6):336-341. PubMed ID: 32496631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Level of plasma fibronectin and its biological activity in patients with ovarian cancer].
    Kharrasov AF; Safina NA; Moroz IP; Zinkevich OF
    Vopr Onkol; 1991; 37(5):572-6. PubMed ID: 1767512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.
    Piafsky KM; Borgá O; Odar-Cederlöf I; Johansson C; Sjöqvist F
    N Engl J Med; 1978 Dec; 299(26):1435-9. PubMed ID: 82206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The content of fibronectin in the blood of patients with psoriasis].
    Vasil'eva NIu; Nazimova SV; Tatarinov IuS
    Lab Delo; 1991; (3):27-8. PubMed ID: 1710713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating fibrocytes and Crohn's disease.
    Sahebally SM; Burke JP; Chang KH; Kiernan MG; O'Connell PR; Coffey JC
    Br J Surg; 2013 Nov; 100(12):1549-56. PubMed ID: 24264775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crohn's disease in three Sudanese patients.
    Masri SH; Satir AA
    East Afr Med J; 1975 May; 52(5):284-93. PubMed ID: 1157733
    [No Abstract]   [Full Text] [Related]  

  • 34. [Balloon dilatation for intestinal stricture in Crohn's disease].
    Tsujikawa T; Bamba S; Saito Y
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():383-6. PubMed ID: 23126122
    [No Abstract]   [Full Text] [Related]  

  • 35. Potential urinary biomarkers of disease activity in Crohn's disease.
    Markó L; Szigeti N; Szabó Z; Böddi K; Takátsy A; Ludány A; Koszegi T; Molnár GA; Wittmann I
    Scand J Gastroenterol; 2010 Dec; 45(12):1440-8. PubMed ID: 20653491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Crohn's diseases. II. Pathologic analysis of 60 cases (author's transl)].
    Liu TH
    Zhonghua Nei Ke Za Zhi; 1981 Feb; 20(2):85-8. PubMed ID: 7307724
    [No Abstract]   [Full Text] [Related]  

  • 37. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis.
    Geboes KP; Cabooter L; Geboes K
    Acta Gastroenterol Belg; 2000; 63(4):371-6. PubMed ID: 11233520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease?
    Louis E; Reenaers C; Belaiche J
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S59-60. PubMed ID: 18816759
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?
    Argollo M; Gilardi D; Roda G; Fiorino G; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):47-56. PubMed ID: 30848192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of plasma fibronectin concentration in type 1 diabetic patients].
    Zozulińska D; Derc K; Majchrzak A; Szczepanik A; Wierusz-Wysocka B
    Pol Arch Med Wewn; 1999 Sep; 102(3):773-7. PubMed ID: 10949884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.